Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 20 Nov 2026
₹84.16
Change
+1.94 (2.36%)
Open
₹81.0
Prev. Close
₹82.22
Day High
₹84.8
Day Low
₹80.3
Volume Analysis
Traded
4,063,686
Delivered
1,994,967
Delivery %
49.09%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (3)
- •Trading within 3% of its 52-week high (₹85.1)
- •Strong return on equity (28.9%)
- •Strong operating margin (58.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (49.4%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹90.38 | ₹87.59 | ₹85.88 | ₹83.09 | ₹81.38 | ₹78.59 | ₹76.88 |
| Fibonacci | ₹87.59 | ₹85.87 | ₹84.81 | ₹83.09 | ₹81.37 | ₹80.31 | ₹78.59 |
| Camarilla | ₹85.4 | ₹84.99 | ₹84.57 | ₹83.09 | ₹83.75 | ₹83.34 | ₹82.92 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
—
1 Month
—
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹5.04
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
50.09%
Net margin 38.94% × asset turnover 0.96x × equity multiplier 1.34x
Company Overview
Sector
Healthcare
Market Cap
₹3,724 Cr
P/E (TTM)
84.0
ROE
28.9%
Book Value
₹2.69
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Shukra Medtech Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹85.1); strong return on equity (28.9%). Strong 3-year EPS growth (49.4%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 20 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Stock is trading at 31.3 times its book value
- −Debtor days have increased from 123 to 148 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NSE approved name change to Shukra Medtech Limited and symbol SHUKRAMED, effective November 20, 2026.
Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.
No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.
Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 | 44 |
| Expenses + | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 4 | 26 |
| Operating Profit | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | 0 | 27 | 1 | 19 | 19 |
| OPM % | 21.0% | 51.0% | 41.0% | 25.0% | 12.0% | 37.0% | 55.0% | 24.0% | -7.0% | 69.0% | 11.0% | 81.0% | 42.0% |
| Other Income + | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 18 | 18 |
| Tax % | 0.0% | 1.0% | 24.0% | 41.0% | 39.0% | 23.0% | 29.0% | 26.0% | -1,090.0% | 24.0% | 553.0% | 29.0% | 29.0% |
| Net Profit + | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 13 | 13 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 562 | 721 | -76 | -84 | -77 | — | — | — | — | 270 | -52 | 336 | 652 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 113 |
| Expenses + | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 48 |
| Operating Profit | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 66 |
| OPM % | -10.0% | 24.0% | 28.0% | 30.0% | 29.0% | 13.0% | 13.0% | 14.0% | 9.0% | 26.0% | 39.0% | 51.0% | 58.0% |
| Other Income + | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 63 |
| Tax % | 52.0% | 66.0% | 52.0% | 45.0% | 37.0% | 82.0% | -90.0% | 26.0% | 1.0% | 7.0% | 28.0% | 23.0% | — |
| Net Profit + | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 44 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Dividend Payout % | 0.0% | 0.0% | 16.0% | 15.0% | 17.0% | 0.0% | 0.0% | 10.0% | 4.0% | 6.0% | 5.0% | 2.0% | — |
| Sales growth | -41 | 85 | 7 | 4 | 6 | 109 | -6 | 83 | 187 | 27 | — | 74 | 222 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 | 74 |
| Borrowings + | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 | 22 |
| Other Liabilities + | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 | 34 |
| Total Liabilities | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 175 |
| Fixed Assets + | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 | 21 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 | 26 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 | 128 |
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 | 175 |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 | 44 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | 3 | 0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Cash from Investing Activity + | 1 | 0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Cash from Financing Activity + | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -1 | 2 | -1 | -4 | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 812 | 237 | 7 | 63 | 25 | 81 | 38 | 292 | 64 | -24 | 92 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.2% |
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.43% |
| DII | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.21% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shukra Medtech Limited (this stock) | 3,724 | 84.0 | 31.3 | 28.9% |
| Shukra Pharmaceuticals L | 3,639 | 82.1 | 30.56 | 28.9% |
| Unichem Laboratories Ltd | 3,511 | 29.5 | 1.26 | 3.17% |
| Rpg Life Sciences Ltd | 4,310 | 37.6 | 6.26 | 19.3% |
| Advanced Enzyme Tech Ltd | 3,102 | 19.1 | 1.9 | 10.5% |
| Kwality Pharmaceuticals L | 4,370 | 45.3 | 11.31 | 22.6% |
| Solara Active Pha Sci Ltd | 3,039 | 64.2 | 2.11 | -0.13% |
Which Mutual Funds Hold Shukra Medtech Limited?
Frequently Asked Questions about Shukra Medtech Limited
Shukra Medtech Limited (SHUKRAMED) closed at ₹84.16 on NSE on 20 November 2026, up 1.94 (2.36%) from the previous close.
Shukra Medtech Limited trades on the NSE (National Stock Exchange of India) under the symbol SHUKRAMED.
Shukra Medtech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 84.0.
Shukra Medtech Limited has a dividend yield of 0.01%.
Shukra Medtech Limited's 52-week high is ₹85.1 and its 52-week low is ₹26.3.
Shukra Medtech Limited has a market capitalisation of ₹3,724 crore.
Shukra Medtech Limited has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shukra Medtech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.